NeOnc Is Putting Two Brain Cancer Programs on the Global Stage
Globe Newswire•02/11/2026•11:00 ET
3
Key Highlights
- ➤Two NEO100 and NEO212 posters scheduled for November 13 at SNO’s annual meeting
- ➤NEO212 completed Phase 1 dose escalation and is advancing toward Phase 2 development
- ➤Proposed pivotal trial targets approximately 500 patients across 30 hospitals in three countries
- ➤877,000 NTHI shares reported short, equal to approximately 5.6 days of trading volume
- ➤Roth Capital initiated Buy coverage with a $20 price target for NTHI
Expert Statements
Wallace, Physician
“We can't see it, actually, at this moment.”
Jonathan Aschoff, Analyst at Roth Capital
“Buy”
DENVER, Nov. 02, 2026 (GLOBE NEWSWIRE) -- (247MarketNews.com) — In a market where the latest investment trends often dominate attention, NeOnc Technologies Holdings (NASDAQ: NTHI) is developing a story that could prove far more meaningful.
The clinical-stage biopharmaceutical company is advancing potential treatments for some of the most difficult-to-treat brain cancers while building an ambitious clinical development strategy that could reach approximately 500 patients across 30 hospitals in three countries.
Get started
Create a free account to read the full story.